Intermediate endpoints as surrogates for outcomes in cancer immunotherapy: a systematic review and meta-analysis of phase 3 trials

BACKGROUND: Cancer immunotherapy shows unique efficacy kinetics that differs from conventional treatment. These characteristics may lead to the prolongation of trial duration, hence reliable surrogate endpoints are urgently needed. We aimed to systematically evaluate the study-level performance of c...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhishan, Pan, Qunxiong, Lu, Mingdong, Zhao, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432823/
https://www.ncbi.nlm.nih.gov/pubmed/37600482
http://dx.doi.org/10.1016/j.eclinm.2023.102156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432823/
https://www.ncbi.nlm.nih.gov/pubmed/37600482
http://dx.doi.org/10.1016/j.eclinm.2023.102156

Ejemplares similares